Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02295969|
Recruitment Status : Completed
First Posted : November 20, 2014
Last Update Posted : July 26, 2017
|Condition or disease||Intervention/treatment|
The purpose of this study is to further describe the safety and tolerability of ORALAIR tablets in children 5 to 9 years of age with grass-pollen-induced allergic rhinitis with or without conjunctivitis.
Patients are followed for safety and tolerability during the first 30 treatment days.
|Study Type :||Observational|
|Actual Enrollment :||307 participants|
|Official Title:||An Observational Study of ORALAIR® (Grass Pollen Allergen Extract From: Cocksfoot, Sweet Vernal, Rye Grass, Meadow Grass, Timothy) Tablet for Sublingual Use in Children 5 to 9 Years of Age With Grass-pollen-induced Allergic Rhinitis With or Without Conjunctivitis|
|Study Start Date :||December 2014|
|Actual Primary Completion Date :||July 3, 2017|
|Actual Study Completion Date :||July 3, 2017|
- Drug: Oralair
Observational study, Oralair is used as prescribed by the prescriber phycisian.
- All adverse events that started on or after the day the first dose of Oralair [ Time Frame: During 30 days after the date of the first dose ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02295969
|Klinikum Augsburg, Klinik für Kinder und Jugendliche|
|Augsburg, Bavaria, Germany, 86156|